U.S., Jan. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07337525) titled 'A First in Human Study of PLT012 in Participants With Solid Tumor Cancers' on Jan. 02.
Brief Summary: The goal of this clinical trial is to learn about what doses of PLT012 are safe to use in adults with advanced cancers in solid tumors. It will also learn about how effective different doses of PLT012 are in treating cancer. The main questions it aims to answer are:
What adverse events and toxicities (harmful side effects) are associated with different doses of PLT012? What are the blood levels of PLT012 in your body at different timepoints? What effect does PLT012 have on reducing tumor size and/or preventing the worsening of canc...